USDJPY jumps on vaccine progress
The long term trend remains bearish despite today's surge: Chart
Share this:
The US Dollar was bearish against most of its major pairs on Monday with the exception of the CHF, JPY and EUR. On the US economic data front, no major economic data was released. In other news, over the weekend Democratic Presidential nominee Joe Biden declared victory in the 2020 Presidential election.
On Tuesday, the National Federation of Independent Business's Small Business Optimism Index for October is expected to increase to 104.2 on month, from 104.0 in September. Finally, the Bureau of Labor Statistics' Job Openings for September is expected to rise to 6,500 on month, compared to 6,493 in August.
The Euro was bearish against most of its major pairs with the exception of the CHF and JPY. In Europe, The German Federal Statistical Office has posted September trade balance at 20.8 billion euros (vs 16 billion euros surplus expected). Separately, Europe Sentix Investor Confidence for November was released at -10, vs -15 expected and -8.3 in October. Also, Bank of France Industrial Sentiment for October was published at 97, vs 90 expected.
The Australian dollar was bullish against most of its major pairs with the exception of the NZD.
One of the most active pairs on Monday was the USD/JPY which jumped 201 pips amid a U.S. market rally on hopes of a coronavirus vaccine from Pfizer (PFE) and BioNTech SE (BNTX) after their vaccine trials were found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior COVID-19 infection.
Looking at a chart of the USDJPY, The pair surged off of 103.18 support however price action remains contained inside a declining trend channel. Key resistance has been identified at the 106.10 level. A break above could have strong bullish implications. For now, the preference is to ride the trend lower ultimately reaching the 102 support level.
Source: GAIN Capital, TradingView
Happy Trading
On Tuesday, the National Federation of Independent Business's Small Business Optimism Index for October is expected to increase to 104.2 on month, from 104.0 in September. Finally, the Bureau of Labor Statistics' Job Openings for September is expected to rise to 6,500 on month, compared to 6,493 in August.
The Euro was bearish against most of its major pairs with the exception of the CHF and JPY. In Europe, The German Federal Statistical Office has posted September trade balance at 20.8 billion euros (vs 16 billion euros surplus expected). Separately, Europe Sentix Investor Confidence for November was released at -10, vs -15 expected and -8.3 in October. Also, Bank of France Industrial Sentiment for October was published at 97, vs 90 expected.
The Australian dollar was bullish against most of its major pairs with the exception of the NZD.
One of the most active pairs on Monday was the USD/JPY which jumped 201 pips amid a U.S. market rally on hopes of a coronavirus vaccine from Pfizer (PFE) and BioNTech SE (BNTX) after their vaccine trials were found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior COVID-19 infection.
Looking at a chart of the USDJPY, The pair surged off of 103.18 support however price action remains contained inside a declining trend channel. Key resistance has been identified at the 106.10 level. A break above could have strong bullish implications. For now, the preference is to ride the trend lower ultimately reaching the 102 support level.
Source: GAIN Capital, TradingView
Happy Trading
The US Dollar was bearish against most of its major pairs on Monday with the exception of the CHF, JPY and EUR. On the US economic data front, no major economic data was released. In other news, over the weekend Democratic Presidential nominee Joe Biden declared victory in the 2020 Presidential election.
On Tuesday, the National Federation of Independent Business's Small Business Optimism Index for October is expected to increase to 104.2 on month, from 104.0 in September. Finally, the Bureau of Labor Statistics' Job Openings for September is expected to rise to 6,500 on month, compared to 6,493 in August.
The Euro was bearish against most of its major pairs with the exception of the CHF and JPY. In Europe, The German Federal Statistical Office has posted September trade balance at 20.8 billion euros (vs 16 billion euros surplus expected). Separately, Europe Sentix Investor Confidence for November was released at -10, vs -15 expected and -8.3 in October. Also, Bank of France Industrial Sentiment for October was published at 97, vs 90 expected.
The Australian dollar was bullish against most of its major pairs with the exception of the NZD.
One of the most active pairs on Monday was the USD/JPY which jumped 201 pips amid a U.S. market rally on hopes of a coronavirus vaccine from Pfizer (PFE) and BioNTech SE (BNTX) after their vaccine trials were found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior COVID-19 infection.
Looking at a chart of the USDJPY, The pair surged off of 103.18 support however price action remains contained inside a declining trend channel. Key resistance has been identified at the 106.10 level. A break above could have strong bullish implications. For now, the preference is to ride the trend lower ultimately reaching the 102 support level.
Source: GAIN Capital, TradingView
Happy Trading
On Tuesday, the National Federation of Independent Business's Small Business Optimism Index for October is expected to increase to 104.2 on month, from 104.0 in September. Finally, the Bureau of Labor Statistics' Job Openings for September is expected to rise to 6,500 on month, compared to 6,493 in August.
The Euro was bearish against most of its major pairs with the exception of the CHF and JPY. In Europe, The German Federal Statistical Office has posted September trade balance at 20.8 billion euros (vs 16 billion euros surplus expected). Separately, Europe Sentix Investor Confidence for November was released at -10, vs -15 expected and -8.3 in October. Also, Bank of France Industrial Sentiment for October was published at 97, vs 90 expected.
The Australian dollar was bullish against most of its major pairs with the exception of the NZD.
One of the most active pairs on Monday was the USD/JPY which jumped 201 pips amid a U.S. market rally on hopes of a coronavirus vaccine from Pfizer (PFE) and BioNTech SE (BNTX) after their vaccine trials were found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior COVID-19 infection.
Looking at a chart of the USDJPY, The pair surged off of 103.18 support however price action remains contained inside a declining trend channel. Key resistance has been identified at the 106.10 level. A break above could have strong bullish implications. For now, the preference is to ride the trend lower ultimately reaching the 102 support level.
Source: GAIN Capital, TradingView
Happy Trading
Latest market news
Open an account in minutes
Experience award-winning platforms with fast and secure execution, and enjoy tight spreads from 0.5 pts on FX and 0.3 pts on indices.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
AUD/USD Q4 Outlook: RBA and Fed Hikes Set the Tone
AUD/USD enters Q4 with RBA and Fed hikes in focus as sticky inflation, rising unemployment and US dollar strength shape the Australian dollar.
USD/JPY Q4 2026 Outlook: Hawkish Fed Pricing Clashes With Intervention Risk
The year-end tug-of-war is clear: hawkish Fed pricing supports USD/JPY, while intervention risk limits the upside.
Japanese Yen Forecast: USD/JPY 4% Rally Challenges Post-Intervention Downtrend 9 24 2026
USD/JPY momentum has shifted sharply higher, putting a major resistance confluence in focus as U.S. and Japanese event risk builds.
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
StoneX Financial Pte. Ltd. is not under any obligation to update this report.
Trading CFDs carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.forex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.